Cargando…

Management of Coronary Artery Spasm

Calcium channel blockers (CCBs) are the first-line treatment for coronary artery spasm (CAS). When CAS-related angina symptoms are not well controlled by CCB therapy, long-acting nitrates or (where available) nicorandil can be added as second-line medications. In the case of CAS refractory to standa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanza, Gaetano Antonio, Shimokawa, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345953/
https://www.ncbi.nlm.nih.gov/pubmed/37456765
http://dx.doi.org/10.15420/ecr.2022.47
_version_ 1785073206237855744
author Lanza, Gaetano Antonio
Shimokawa, Hiroaki
author_facet Lanza, Gaetano Antonio
Shimokawa, Hiroaki
author_sort Lanza, Gaetano Antonio
collection PubMed
description Calcium channel blockers (CCBs) are the first-line treatment for coronary artery spasm (CAS). When CAS-related angina symptoms are not well controlled by CCB therapy, long-acting nitrates or (where available) nicorandil can be added as second-line medications. In the case of CAS refractory to standard treatments, several other alternative drugs and interventions have been proposed, including the Rho-kinase inhibitor fasudil, anti-adrenergic drugs, neural therapies and percutaneous coronary interventions. In patients with syncope or cardiac arrest caused by CAS-related tachyarrhythmias, or even bradyarrhythmias, implantation of an ICD or pacemaker, respectively, should be considered according to the risk of recurrence and efficacy of vasodilator therapy.
format Online
Article
Text
id pubmed-10345953
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Radcliffe Cardiology
record_format MEDLINE/PubMed
spelling pubmed-103459532023-07-15 Management of Coronary Artery Spasm Lanza, Gaetano Antonio Shimokawa, Hiroaki Eur Cardiol Ischaemic Heart Disease Calcium channel blockers (CCBs) are the first-line treatment for coronary artery spasm (CAS). When CAS-related angina symptoms are not well controlled by CCB therapy, long-acting nitrates or (where available) nicorandil can be added as second-line medications. In the case of CAS refractory to standard treatments, several other alternative drugs and interventions have been proposed, including the Rho-kinase inhibitor fasudil, anti-adrenergic drugs, neural therapies and percutaneous coronary interventions. In patients with syncope or cardiac arrest caused by CAS-related tachyarrhythmias, or even bradyarrhythmias, implantation of an ICD or pacemaker, respectively, should be considered according to the risk of recurrence and efficacy of vasodilator therapy. Radcliffe Cardiology 2023-05-22 /pmc/articles/PMC10345953/ /pubmed/37456765 http://dx.doi.org/10.15420/ecr.2022.47 Text en Copyright © 2023, Radcliffe Cardiology https://creativecommons.org/licenses/by-nc/4.0/This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.
spellingShingle Ischaemic Heart Disease
Lanza, Gaetano Antonio
Shimokawa, Hiroaki
Management of Coronary Artery Spasm
title Management of Coronary Artery Spasm
title_full Management of Coronary Artery Spasm
title_fullStr Management of Coronary Artery Spasm
title_full_unstemmed Management of Coronary Artery Spasm
title_short Management of Coronary Artery Spasm
title_sort management of coronary artery spasm
topic Ischaemic Heart Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345953/
https://www.ncbi.nlm.nih.gov/pubmed/37456765
http://dx.doi.org/10.15420/ecr.2022.47
work_keys_str_mv AT lanzagaetanoantonio managementofcoronaryarteryspasm
AT shimokawahiroaki managementofcoronaryarteryspasm